OCUL - Company ID 0001393434
The table below shows OCULAR THERAPEUTIX, INC's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $10.79M | $14.54M | $13.46M | $10.70M | $15.43M | $16.44M |
| Cost of revenue | $1.33M | $1.77M | $1.94M | $1.26M | $1.56M | $1.51M |
| Gross profit | - | - | - | - | - | - |
| R&D | $66.21M | $52.36M | $51.08M | $42.86M | $37.05M | $28.86M |
OCULAR THERAPEUTIX, INC reported annual revenue of $51.95M for fiscal year 2025. That is down 18.5% from $63.72M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $1.89M (FY 2016) to $51.95M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $20.01M |
| $16.02M |
| $14.35M |
| $16.35M |
| $12.23M |
| $19.67M |
| Operating income | -$93.34M | -$68.70M | -$67.64M | -$63.92M | -$46.00M | -$43.59M |
| Income tax | - | - | - | - | - | - |
| Net income | -$88.61M | -$69.42M | -$67.81M | -$64.05M | -$36.49M | -$43.78M |
| EPS (diluted) | -$0.40 | -$0.38 | -$0.39 | -$0.38 | -$0.22 | -$0.26 |